2023年6月23日

RxLightning——一个创造者的行业首个全面精简专业药物平台访问和负担能力——宣布关闭一系列1750万美元投资来支持公司的成长,进一步消除阻碍拯救生命的治疗。这一轮融资是由LRVHealth, McKesson企业和现有投资者的参与诺华(dRx资本),Onco360 (BrightSpring卫生服务)、赫斯特公司,HealthX企业。这些投资带来RxLightning自《盗梦空间》的总资金为2050万美元。通过RxLightning,卫生保健提供者——从这些练习独立诊所大型卫生系统——利用简化工作流完成多步专业药物新员工培训过程在几分钟内。和公司的MedAccess生态系统是一个集成的平台,为病人提供了透明访问和可购性旅程为医生、患者、专业药房,药品制造商,减少行政负担和使新员工培训支持。专业药物市场代表在美国超过一半的药物支出总额,reaching $301 billion in 2021, according to data from the U.S. Department of Health and Human Services. And despite this growing reliance on advanced therapies, accessing these medications remains a slow, manual, and costly process. Plus every specialty medication currently requires a custom paper form that a provider or patient must complete. These forms are then pushed through a manual process outside the electronic health record (EHR), which can result in significant care delays. RxLightning is known as the single destination to enroll patients for any specialty medication – brand or generic – at any specialty pharmacy. And the company has digitized forms for over 1,200 specialty drugs with custom logic and smart-pick menus, and continuously adds forms for new medications as they enter the market. Plus the modular platform automates the FDA’s Risk Evaluation and Mitigation Strategies (REMS) program, confirms patient eligibility and coverage, and streamlines enrollment in financial assistance programs to further eliminate access barriers. Through RxLightning, providers and patients can complete the entire onboarding process in minutes or hours rather than days or weeks. In connection with this funding round, LRVHealth’s Josh Flum and McKesson Ventures’ Carrie Williams will join RxLightning’s board of directors alongside HealthX Ventures’ Mark Bakken, former Walgreens executive Brad Fluegel, and Julia Regan. RxLightning is available at no cost to healthcare providers and helps them get patients started on specialty medications at lightning speed. KEY QUOTES: “Many people have tried to fix the slow, manual specialty medication onboarding process, but they’ve approached it with a single drug, pharmacy, or isolated part of the process in mind. RxLightning is the first to provide an end-to-end solution that covers the entire market – from every medication and destination to every stakeholder in the process. This new investment will help us further scale our medication access capabilities, support infrastructure and personnel growth, and maintain the unprecedented rate at which we’ve grown our partner base – all while receiving strategic guidance from leading industry experts.” — Julia Regan, CEO and founder at RxLightning “RxLightning has gone far beyond creating a digital experience that replaces paper forms, and has created a first-of-its-kind ecosystem that connects every part of the specialty medication process. As the specialty market continues to grow and transform the treatment of diseases, RxLightning will play an important role in improving access while minimizing cost and burden on the system. We’re proud to be standing alongside such a talented team on this journey.” — Josh Flum, managing partner at LRVHealth “RxLightning addresses the tedious administrative burden faced by providers when trying to initiate patients on specialty medications. The complexity will only increase as new drugs entering the market require even more nuanced clinical, financial, and logistical considerations to ensure patients get access to medications as efficiently as possible. It’s rare to find a company that is so truly aligned across pharma, payer, provider, and patient needs.” — Carrie Williams, partner for McKesson Ventures Trending on Pulse 2.0